Donald Sesso, DO
Otolaryngology/Facial Plastic Surgery · Norristown, PANPI 1558437566
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $18,500 of the $22,929 with a category attached, or 80.7%. Optinose US, Inc. accounts for 84.6% of it on its own, with 26 other manufacturers making up the rest. Among otolaryngology/facial plastic surgery clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 113 payments — averaging $202.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Optinose US, Inc.$19K
- Aerin Medical Inc.$1K
- Intersect ENT, Inc.$313
- Acclarent, Inc$211
- Zimmer Biomet$136
- Medtronic$136
- plus $1K from 21 others
What the payments were for
- Consulting fees$1000%
- Speaking & faculty fees$18,50081%
- Travel & lodging$1,2325%
- Food & beverage$3,09714%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Optinose US, Inc. | 69 | $19,395 |
| Aerin Medical Inc. | 5 | $1,325 |
| Intersect ENT, Inc. | 4 | $313 |
| Acclarent, Inc | 4 | $211 |
| Zimmer Biomet | 1 | $136 |
| Medtronic | 2 | $136 |
| AstraZeneca | 2 | $121 |
| Mallinckrodt Hospital Products Inc. | 1 | $115 |
| Biocryst US Sales Co., LLC | 1 | $115 |
| Phathom Pharmaceuticals, Inc. | 1 | $115 |
| Valeritas, Inc. | 1 | $114 |
| Biohaven Pharmaceuticals, Inc. | 1 | $113 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $113 |
| GSK | 6 | $107 |
| Insmed, Inc. | 1 | $106 |
| Sanofi-aventis U.S. LLC | 1 | $104 |
| Stryker | 1 | $55 |
| Regeneron Healthcare Solutions, Inc. | 2 | $50 |
| Neurent Medical Limited | 1 | $40 |
| Integra Lifesciences Corporation | 1 | $23 |
| Merck | 1 | $22 |
| Bard Access Systems, Inc. | 1 | $21 |
| Paratek Pharmaceuticals, Inc. | 1 | $18 |
| Hikma Pharmaceuticals USA | 1 | $18 |
| Kowa Pharmaceuticals America, Inc. | 1 | $16 |
| Acelrx Pharmaceuticals, Inc. | 1 | $15 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Xhance$18,967
- VivAer$1,191
- RhinAer$1,191
- NURTEC ODT$226
- DVR Crosslock Plates/Screws/Pegs$136
- TruDi Nav Cable$120
- ACTHAR$115
- Orladeyo$115
- VOQUEZNA$115
- V-GO$114
- PRALUENT$104
- FARXIGA$104
- PROPEL$100
How this compares
$22,929 in reported general payments places this provider in the 95th percentile of 21 otolaryngology/facial plastic surgery providers in Pennsylvania.
See all otolaryngology/facial plastic surgery providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Azelastine Hcl | 523 | $15,833 |
| Ipratropium Bromide | 293 | $11,586 |
| XhanceFluticasone Propionate | 16 | $10,727 |
| Fluticasone Propionate | 518 | $8,606 |
| Fluocinolone Acetonide Oil | 129 | $5,073 |
| Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth | 38 | $4,625 |
| Famotidine | 463 | $4,583 |
| Omeprazole | 349 | $3,670 |
| CefuroximeCefuroxime Axetil | 154 | $3,364 |
| Budesonide | 11 | $2,329 |
| Lansoprazole | 20 | $1,634 |
| Montelukast Sodium | 134 | $1,556 |
| Methylprednisolone | 247 | $1,337 |
| Hydrocortisone-Acetic AcidHydrocortisone/Acetic Acid | 11 | $901 |
| Mupirocin | 110 | $761 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Optinose US, Inc.Xhance | $19,395 | $10,72716 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 21 otolaryngology/facial plastic surgery providers in Pennsylvania.
Other otolaryngology/facial plastic surgery in Norristown
- Jason BloomBryn Mawr$718K
- Sean CarrollErie$6K
- Melissa SchwartzElkins Park$5K
- Adam MariottiExton$5K
- Jeffrey BrigliaLanghorne$4K
- Aykut UnsalPhiladelphia$4K
- Michael PicarielloExton$4K
- Raphael GabayPhiladelphia$4K
- Jose UribeBethlehem$4K
- Harleen SethiPhiladelphia$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.